Seeking Alpha
26 Nov 2025, 21:03 UTC · 44w ago
Impact · against what's priced in
Ironwood Pharmaceuticals faces a mixed outlook where strong Linzess revenue growth is undermined by regulatory setbacks for apraglutide and a failed acquisition. Takeda gains a competitive advantage as its product Gattex outperformed Ironwood's lead pipeline candidate in head-to-head trials.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA is requiring an additional confirmatory study for apraglutide after it failed to surpass Takeda's Gattex in Phase 3 trials.
More negative than 99% of claims this week
Linzess sales grew 40% year-on-year in Q3 2025 and received new pediatric approval.
So whatStrong immediate top-line growth and market expansion provide a significant fundamental cushion for the company's valuation.
Continue reading
5 related stories
Takeda's Gattex demonstrated superiority over Ironwood's apraglutide in Phase 3 trials, strengthening Takeda's competitive position in the market.
Read from the article alone
No priced-in read yet
While Linzess sales grew 40% year-on-year and expanded into pediatric use, the stock is weighed down by a failed $1bn acquisition and the FDA's requirement for an additional confirmatory study for apraglutide.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 93% of claims this week
Linzess faces a patent expiry in 2029.
So whatThe loss of exclusivity for the primary revenue driver creates a long-term valuation cliff that investors must price in.
More negative than 86% of claims this week
Ironwood Pharmaceuticals' $1bn acquisition of Vectiv Bio failed.
More negative than 70% of claims this week
Which stocks this story touches
More positive than 64% of ticker scores this week
Their product Gattex outperformed Ironwood's apraglutide in Phase 3 trials.
More positive than 54% of ticker scores this week
Strong revenue growth and new pediatric approval are offset by a failed acquisition and FDA requirements for further studies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
7h ago
−2.6%
Price is moving against the score
$3.76 vs $3.86 close before publication (Nov 26) · not market-adjusted
IRWD chart →+24.7%
Price agrees with the score
$18.10 vs $14.52 close before publication (Nov 26) · not market-adjusted
TAK chart →
